Read our Press Releases...


Renascent Group on YouTube




click on the icon to Renascent Groups YouTube video site

Social Networks:

Join Our Networking Group


The Renascent Group is also a member of: 

When ever you see these names and logo's, simply click on the name/logo to see what is happening.

Wit & Wisdom Corner

October 2011
  • “We're here to put a dent in the universe. " ~ Steve Jobs, entrepreneur and inventor (1955-2011)

Press Releases

Press Releases From Renascent Group

Renascent Group Executive Search partners with Agennix to Hire Christine Boisclair
Senior Vice President of Global Regulatory Affairs

Planegg/Munich (Germany), Princeton, NJ and Houston, TX, July 20, 2011 – Agennix AG (Frankfurt Stock Exchange: AGX) today announced the appointment of Christine Boisclair as Senior Vice President, Global Regulatory Affairs, reporting to Dr. Rajesh Malik, Chief Medical Officer.  In this position, Ms. Boisclair will lead all global regulatory, quality and compliance activities for Agennix, including regulatory filings for talactoferrin.
Rajesh Malik, M.D., Chief Medical Officer, said, “I am very pleased to welcome Christine Boisclair to Agennix.  She has a strong track record of getting drugs approved in both Europe and the U.S., including a drug for non-small cell lung cancer.  Her extensive expertise in overseeing novel therapies through the regulatory review process will be invaluable as we advance talactoferrin through development and prepare for a potential regulatory filing if the FORTIS-M trial is positive.”
Ms. Boisclair has over twenty years of U.S. and European regulatory affairs experience, covering both drugs and biologics in a variety of therapeutic areas, including oncology and anti-infectives. She joins Agennix from OSI Pharmaceuticals, Inc., where she worked for over ten years in positions of increasing responsibility, most recently serving as Vice President, Regulatory Affairs.  At OSI, she built up the regulatory affairs department and served as the regulatory lead for the successful New Drug Application (NDA) for Tarceva® (erlotinib) in non-small cell lung cancer (NSCLC), as well as the subsequent supplemental NDAs for pancreatic cancer and NSCLC maintenance.  Prior to OSI, she worked at several biotechnology and pharmaceutical companies, including Genzyme Corporation, GD Searle & Co. and Glaxo Group Research.  She holds a Bachelor of Science Honors Degree in Biochemistry from York University, York, England.
Trenton Beriont, President and Owner of Renascent Group Executive Search says, “We  
are proud to have worked with Agennix in the hiring of Christine Boisclair for the role  
of SVP and look forward to assisting Agennix in the future.”